Compare VREX & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VREX | AVXL |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 483.7M | 397.6M |
| IPO Year | N/A | N/A |
| Metric | VREX | AVXL |
|---|---|---|
| Price | $13.93 | $5.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $16.67 | ★ $22.00 |
| AVG Volume (30 Days) | 300.0K | ★ 2.0M |
| Earning Date | 02-05-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $844,600,000.00 | N/A |
| Revenue This Year | $4.79 | N/A |
| Revenue Next Year | $4.15 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.14 | N/A |
| 52 Week Low | $6.76 | $2.86 |
| 52 Week High | $15.46 | $13.99 |
| Indicator | VREX | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 75.49 | 67.85 |
| Support Level | $13.02 | $4.67 |
| Resistance Level | $13.99 | $4.44 |
| Average True Range (ATR) | 0.51 | 0.29 |
| MACD | 0.15 | 0.18 |
| Stochastic Oscillator | 95.22 | 89.40 |
Varex Imaging Corp designs and manufactures X-ray imaging components. It operates in two segments Medical and Industrial. The Medical segment, which is the key revenue driver, designs, manufactures, sells, and services X-ray imaging components, including X-ray tubes, digital detectors and accessories, generators, and heat exchangers among other products. The Industrial segment designs, manufactures, sells, and services Linatron X-ray accelerators, X-ray tubes, digital flat panel detectors, high-voltage connectors, and coolers. Geographically, the company generates maximum revenue from Europe, Middle East, and Africa (EMEA) and the rest from the Americas and Asia Pacific region.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.